Bone Metastases and the @entity470 and XXXX Mutation Status in @entity2220 - The Results of Three Year Retrospective Analysis.

@entity1 @entity984 @entity470 @entity2 @entity3 @entity2220
UNASSIGNED: @entity2 is a heterogeneous group of disease and mutational profiling of @entity2220 is a routine practice in thoracic oncology. @entity984 ( @entity984 ) and @entity470 mutations play an important role in the carcinogenesis of a subset of @entity2220 . Our aim was to investigate the correlation between bone @entity3 and @entity470 and @entity984 mutation status in @entity2220 @entity1 . Retrospectively we analysed 224 @entity1 with recurrent or metastatic @entity2220 . @entity1 were treated with standard chemotherapy as first line therapy and with @entity470 -TK inhibitors as a second or third line therapy. 72 of 224 @entity1 (32  %) had verified bone @entity3 . Bone @entity3 and Skeletal Related Events (SRE) were more frequent in @entity1 , heavy smokers and without treatment of @entity470 TK inhibitors. We have found that @entity470 and @entity984 mutation status are both predictive factors for the treatment efficacy and prognostic factors for the disease progression. However there were no significant correlation between mutation status and the presence of bone @entity3 (P   =   0, 59). In our study the presence of bone @entity3 proved to be an independent prognostic factor related to poor performance status and worse Quality of Life (QL).
